Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa/acne inversa

Abstract

Hidradenitis suppurativa/acne inversa (HS) is associated with numerous and relevant restrictions on the quality of life for those affected and their relatives. The exact prevalence of HS varies significantly across studies, but it is likely to be higher than suggested in previous publications. HS care is associated with high costs for the healthcare system and for those affected. The introduction of biologic therapy has led to additional costs, but also to considerable additional benefits in terms of care. In view of the complexity of diagnostics and therapy, there is aparticular need for optimized care concepts in order to reduce the burden on those affected, their relatives and the healthcare system.